StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Nicotinate

HCID 937
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

Standard-SMILES
O=C([O-])c1cccnc1
InChIKey
PVNIIMVLHYAWGP-UHFFFAOYSA-M
Summenformel
C6H4NO2-
Durchschnittliche Molmasse
122,1 g/mol
Monoisotopische Masse
122,02420337

Überblick

Nicotinate is a pyridinemonocarboxylate that is the conjugate base of nicotinic acid, arising from deprotonation of the carboxy group; major species at pH 7.3. It has a role as a metabolite and a Saccharomyces cerevisiae metabolite. It is a vitamin B3 and a pyridinemonocarboxylate. It is a conjugate base of a nicotinic acid.

Namen und Bezeichner

Bevorzugter Name
Nicotinate
IUPAC
pyridine-3-carboxylate

Namen und Synonyme

nicotinate3-pyridinecarboxylateCHEBI:32544RefChem:927733pyridine-3-carboxylatenico-400-PVNIIMVLHYAWGP-UHFFFAOYSA-MAC-907/25004509AE-848/01496050Q27104221

Datenbank-Bezeichner

PubChem CID
937
ChEBI
CHEBI:32544
Nikkaji
J239.335B

Eigenschaften

Berechnete Struktureigenschaften

XLogP
0,9
Polarare Oberfläche (TPSA)
53 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
0
Schwere Atome
9
Formalladung
-1
Komplexität
108

Experimentelle und physikochemische Eigenschaften

Collision Cross Section · 2 Einträge

121 Ų [M-H]- [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]

124 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

TreatmentSupportive measures should be undertaken in the event of an overdose. (L1712)
Health Effects · 1 Eintrag

Niacin at extremely high doses can have life-threatening acute toxic reactions. Extremely high doses of niacin can also cause niacin maculopathy, a thickening of the macula and retina which leads to blurred vision and blindness. This maculopathy is reversible after stopping niacin intake. Side effects of hyperglycemia, cardiac arrhythmias and birth defects have also been reported. (A729)

Exposure RoutesOral (L1436) ; Intramuscular (L1436). Both nicotinic acid and nicotinamide are efficiently absorbed from the stomach and small intestine.
Toxicity Summary · 1 Eintrag

Niacin binds to Nicotinate D-ribonucleotide phyrophsopate phosphoribosyltransferase, Nicotinic acid phosphoribosyltransferase, Nicotinate N-methyltransferase and the Niacin receptor. Niacin is the precursor to nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are vital cofactors for dozens of enzymes. The mechanism by which niacin exerts its lipid lowering effects is not entirely understood, but may involve several actions, including a decrease in esterification of hepatic triglycerides. Niacin treatment also decreases the serum levels of apolipoprotein B-100 (apo B), the major protein component of the VLDL (very low-density lipoprotein) and LDL fractions.

Signs and Symptoms · 1 Eintrag

Nicotinic acid can cause vasodilation of cutaneous blood vessels resulting in increased blood flow, principally in the face, neck and chest. This produces the niacin- or nicotinic acid-flush. The niacin-flush is thought to be mediated via the prostaglandin prostacyclin. Histamine may also play a role in the niacin-flush. Flushing is the adverse reaction first observed after intake of a large dose of nicotinic acid, and the most bothersome one.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Toxicity DataLD50: 7000 mg/kg (Oral, Rat) (T14) LD50: 730 mg/kg (Intraperitoneal, Rat) (T14) LD50: 3500 mg/kg (Subcutaneous, Mouse) (T14)

Chemie und Industrie

Pharmakologische Informationen

Metabolism/Metabolites · 1 Eintrag

Niacin is rapidly metabolized and undergoes extensive first-pass metabolism in the liver. The drug is converted to several metabolites, including nicotinuric acid (NUA), nicotinamide, and nicotinamide adenine dinucleotide (NAD). At doses used to treat hyperlipoproteinemia, the principal metabolic pathways appear to be saturable, and niacin is thought to exhibit nonlinear, dose-dependent pharmacokinetics. (L1323) Half Life: 20-45 minutes.

MeSH Pharmacological Classification · 3 Einträge

Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.

Drugs used to cause dilation of the blood vessels.

A group of water-soluble vitamins, some of which are COENZYMES.

Verwendung und Herstellung

Uses · 1 Eintrag

For the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy. It can be found in various foods, such as liver, chicken, beef, fish, cereal, peanuts and legumes. Niacin is also used as a pharmaceutical to reverse atherosclerosis. (A729)

Zugehörige Reaktionen

13
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 34899
HRID 34899als Edukt
Reaktionsgleichung von HRID 34900
HRID 34900als Edukt
Reaktionsgleichung von HRID 102188
HRID 102188als Produkt
Reaktionsgleichung von HRID 295972
HRID 295972als Produkt
Reaktionsgleichung von HRID 324688
HRID 324688als Produkt
Reaktionsgleichung von HRID 341516
HRID 341516als Edukt
Reaktionsgleichung von HRID 376482
HRID 376482als Edukt
Reaktionsgleichung von HRID 602234
HRID 602234als Edukt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung